首页> 外文会议>Controlled Release Society annual meeting >Establishment of systemic anti-tumor resistance in mice treated with HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin
【24h】

Establishment of systemic anti-tumor resistance in mice treated with HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin

机译:含有人静脉内免疫球蛋白的HPMA的多柔比星缀合物治疗的小鼠系统抗肿瘤抗性的建立

获取原文

摘要

Anti-cancer efficacy of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate containing doxorubicin and normal human immunoglobulin (Dox- HPMA-HuIg) was studied in C57BL/6 mice with T cell lymphoma EL-4. In a significant proportion of the mice, a complete tumor regression could be induced and specific anti-tumor resistance established. Possible mechanisms of the resistance are discussed.
机译:用T细胞淋巴瘤EL-4研究了含有多霉素和正常人免疫球蛋白(DOX-HPMA-HUIG)的N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物缀合物的抗癌疗效。在大量小鼠中,可以诱导完全肿瘤回归和确定的特异性抗肿瘤抗性。讨论了电阻的可能机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号